Mechanisms of PARP inhibitor sensitivity and resistance
1Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA; Center for DNA Damage and Repair, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.
Abstract:
BRCA1 and BRCA2 deficient tumor cells are sensitive to inhibitors of Poly ADP Ribose Polymerase (PARP1) through the mechanism of synthetic lethality. Several PARP inhibitors, which are oral drugs and generally well tolerated, have now received FDA approval for various ovarian cancer and breast cancer indications. Despite their use in the clinic, PARP inhibitor resistance is common and develops through multiple mechanisms. Broadly speaking, BRCA1/2-deficient tumor cells can become resistant to PARP inhibitors by restoring homologous recombination (HR) repair and/or by stabilizing their replication forks. Here, we review the mechanism of PARP inhibitor resistance.
Insights
Tumor cells with BRCA1/2 deficiencies are vulnerable to Poly ADP Ribose Polymerase (PARP) inhibitors. However, resistance can develop by repairing DNA damage or stabilizing replication forks, limiting treatment effectiveness.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- BRCA1/2 deficient tumors exhibit synthetic lethality with Poly ADP Ribose Polymerase (PARP) inhibitors.
- PARP inhibitors are FDA-approved oral therapies for ovarian and breast cancers.
- Resistance to PARP inhibitors is a significant clinical challenge.
Purpose of the Study:
- To review the mechanisms underlying PARP inhibitor resistance in BRCA1/2-deficient tumors.
- To provide an overview of how cancer cells overcome PARP inhibition.
Main Methods:
- Literature review of studies on PARP inhibitor resistance.
- Analysis of molecular mechanisms contributing to treatment failure.
Main Results:
- Resistance can occur through restoration of homologous recombination (HR) repair pathways.
- Stabilization of replication forks is another key mechanism of resistance.
- Multiple pathways contribute to acquired resistance to PARP inhibitors.
Conclusions:
- Understanding resistance mechanisms is crucial for improving PARP inhibitor efficacy.
- Targeting resistance pathways may offer new therapeutic strategies for ovarian and breast cancer patients.
Related Concept Videos
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Resistivity
Resistance
Equivalent Resistance
Resistance and Conductance
Various factors impact the resistance of a conductor. Spiraling in stranded conductors increases their...
Rolling Resistance
For instance, imagine a hard cylinder rolling on a comparatively soft surface. The cylinder's weight compresses the surface beneath it. As the cylinder moves, the material in front of it slows down due to...


